# EU-1-19-1372_public-assessment-report_20190802_20190802_striascan-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES
HEALTH
26 April 2019
EMA/280752/2019
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Striascan
International non-proprietary name: ioflupane (123I)
Procedure No. EMEA/H/C/004745/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature
deleted.
Official address Domenico Scarlattilaan 6 . 1083 HS Amsterdam . The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
An agency of the European Union
European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged.
Administrative information
Name of the medicinal product:
Striascan
Applicant:
CIS BIO International
Route Nationale 306
Saclay BP 32
91192 Gif-Sur-Yvette
FRANCE
Active substance:
IOFLUPANE (123I)
International non-proprietary
name/Common name:
ioflupane (123I)
Pharmaco-therapeutic group
(ATC Code):
central nervous system, iodine (123I)
compounds
(V09AB03)
Therapeutic indication(s):
This medicinal product is for diagnostic use
only.
Striascan is indicated for detecting loss of
functional dopaminergic neuron terminals in
the striatum:
Pharmaceutical form(s):
Solution for injection
Â· In adult patients with clinically
uncertain parkinsonian syndromes, for
example those with early symptoms, in
order to help differentiate essential
tremor from parkinsonian syndromes
related to idiopathic Parkinson's
disease, multiple system atrophy and
progressive supranuclear palsy.
Striascan is unable to discriminate
between Parkinson's disease, multiple
system atrophy and progressive
supranuclear palsy.
In adult patients, to help differentiate probable
dementia with Lewy bodies from Alzheimer's
disease. Striascan is unable to discriminate
between dementia with Lewy bodies and
Parkinson's disease dementia.
